Green Light Therapy to Treat Migraine

Evidence Review created on 11/09/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Green Light Exposure, Green Light-Emitting Diode Therapy, GLED, Green LED Therapy, Narrow Band Green Light, NbGL, Allay Lamp

Motivation

Green light therapy means sitting for one to two hours in an otherwise dark room lit only by a dim lamp that gives off a narrow band of green light. It is used either daily to prevent migraine attacks or during an attack to ease it. Interest comes from the fact that light is painful during most migraine attacks, which led researchers to ask whether the color of light matters. The proposed explanation is that the eye’s color-sensing cells relay green light to pain-related brain areas differently from other colors.

The approach grew out of laboratory work in two university groups and has since moved into consumer lamps sold for home use. It draws interest because it is drug-free, inexpensive and easy to try, and because many people with frequent migraine either do not tolerate preventive medication or want something to add to it.

This review examines what human studies show about green light for migraine frequency and attack pain, what is known about its harms, who may respond, how the published protocols differ, and how strong and independent the evidence base is.

Benefits - Risks - Protocol - Conclusion

Below are in-depth overviews of green light for migraine and of the light-sensing pathways it is thought to act on.

No directly relevant content from Rhonda Patrick, Peter Attia, Chris Kresser, Life Extension Magazine or Lifespan.io was found: web and on-site searches returned material on other light colors or other migraine treatments only.

Grokipedia

  • Green light therapy for migraine

    A machine-written encyclopedia overview of narrow-band green light for migraine, covering its origin in the Harvard color studies, the consumer lamp and the open-label (participants knew their treatment) real-world study.

Examine

No Examine article on green light therapy exists; the site’s search returns only green tea, green coffee and other supplement pages.

ConsumerLab

No ConsumerLab article on green light therapy exists; the site covers red and near-infrared light therapy and light boxes for seasonal mood disorder, but not green light.

Systematic Reviews

Below are systematic reviews that include the human trials of green light for migraine.

No systematic review or meta-analysis addresses the harms of green light; both reviews above report benefit outcomes only.

Mechanism of Action

Dim green light acts through the eyes: 525 nanometers (nm, light wavelength) at 4–100 lux (illuminance) for 1–2 hours daily (Martin 2021, two authors hold a pending patent), or 520 nm for 2 hours during attacks (Lipton 2023, authors include a lamp-company employee and stock-option holder). Competing explanations:

  • Retina-thalamus route (Burstein group, whose senior author later held green-lamp stock options): In migraine patients, green light produced smaller cone-driven retinal responses (electroretinography, a recording of the eye’s electrical output) than white, blue and red (Noseda 2016), and smaller visual evoked potentials (brain responses to light) than blue, amber and red (Noseda 2016); in rats, headache-signaling thalamic neurons responded least to green (Noseda 2016).
  • Opioid route (Arizona group): In rats, green light-emitting diode (LED) light raised pain thresholds (Ibrahim 2017), increased spinal enkephalins (the body’s own opioid peptides) (Ibrahim 2017) and was reversed by naloxone (an opioid blocker) (Ibrahim 2017); μ- and δ-opioid receptors were required (Martin 2021).
  • Mouse brain circuits: Input from cones (the retina’s color-sensing cells) to enkephalin neurons of the ventral lateral geniculate nucleus (vLGN, a thalamic visual relay) (Tang 2022), or visual cortex projections to the anterior cingulate cortex (ACC, a pain-emotion region) (Cao 2023).
  • Photoreceptor dispute: Removing intrinsically photosensitive retinal ganglion cells (ipRGCs, melanopsin-containing cells driving non-visual light responses) spared mouse pain relief (Tang 2022), whereas a colorblind patient’s response led the Arizona group to propose an ipRGC role (Cheng 2022).
  • Expectation: A systematic review notes nearly all participants knew the color, leaving expectation open (Bain 2026).

Historical Context & Evolution

Narrow-band green light had no earlier therapeutic use; colored light entered migraine research as a trigger to be avoided. Tinted spectacle coatings filtering selected wavelengths were tested to reduce attack light sensitivity (NCT01828684).

In 2016 the Harvard group of Rami Burstein reported that during attacks green light worsened headache in fewer patients than white, blue, amber or red light (Noseda 2016), and that at low intensity it sometimes reduced headache (Noseda 2016); a follow-up confirmed the color preference between attacks (Nir 2018). Independently, the University of Arizona group of Mohab Ibrahim showed green LED pain relief in rats (Ibrahim 2017) and moved to daily green light as migraine prevention; two of its authors hold a pending university patent on green light pain therapy (Martin 2021).

Burstein’s work was commercialized as a narrow-band consumer lamp, evaluated in an open-label study of its buyers whose authors included a company employee and a stock-option holder (Lipton 2023). Health-focused adults were drawn by a drug-free, low-cost option.

Opinion has moved from “green is the least harmful color” toward “green may be therapeutic,” driven by uncontrolled studies and a fixed-order crossover trial (each patient received white light first, then green) (Martin 2021). A double-blind trial (neither participants nor researchers knew the assignment) of lenses passing mainly green light, run by the lens maker, missed its primary endpoint (main outcome) (Posternack 2023), and a 2026 systematic review rated certainty very low (Bain 2026). Neither settles the question: no randomized trial against sham (inactive imitation) light exists.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only trial comparing green light against a light control comes from a single research group, and the second group’s randomized trial used sham brain stimulation, not a light control.

Medium 🟩 🟩

Fewer Monthly Headache Days

Daily preventive sessions of dim green light were followed by fewer headache days in a 29-patient one-way crossover trial by the Arizona group, in which 10 weeks of white light preceded 10 weeks of green light (Martin 2021). Two co-authors hold a pending university patent on green light pain therapy. The fixed order, unblinded color and selection of patients dissatisfied with prior treatment leave time and expectation effects unseparated. A 2026 systematic review rated certainty very low (Bain 2026).

Magnitude: Green phase: 18.4 to 7.4 headache days per month (Martin 2021); white phase: 18.2 to 16.5 days per month (Martin 2021); not compared between groups.

Lower Headache Pain Intensity

Attack pain on the 0–10 numeric pain scale (NPS) fell during the green phase of the Arizona trial (Martin 2021). A second group’s three-arm randomized trial in Pakistan (69 completers) reported lower pain after four weeks of weekday green lamp sessions than after sham transcranial direct current stimulation (tDCS, weak scalp current), all arms continuing usual medication (Mahmood 2025). That comparator was not a light control, and the trial’s median (middle value) baseline score of 4 (Mahmood 2025) sits below its entry threshold of 5 (Mahmood 2025).

Magnitude: Arizona: green phase 8.0 to 3.2 points (Martin 2021), white phase 8.5 to 7.9 points (Martin 2021), not compared between groups. Pakistan: median 4 to 1 with green light (Mahmood 2025) versus 4 to 3 with sham tDCS at four weeks (Mahmood 2025), compared only by rank statistics (comparisons of ordered scores, not raw values).

Scores on the Headache Impact Test-6 (HIT-6, a validated 36–78 disability questionnaire) improved during the green but not the white phase of the Arizona trial (Martin 2021). Migraine-specific quality-of-life scores improved with green light and with active tDCS, with sham tDCS lagging (Mahmood 2025). Both trials share the design limits described above.

Magnitude: In the registry’s 55 chronic-pain participants, with migraine, fibromyalgia and neuropathy pooled, HIT-6 fell 12.85 points during green light (NCT03677206) and 1.14 points during white light (NCT03677206); not compared between groups, and no migraine-only figure is posted.

Low 🟩

Relief During an Ongoing Attack ⚠️ Conflicted

Lamp buyers reported headache improvement in over half of two-hour lamp sessions; authors included a company employee and stock-option holder (Lipton 2023). A double-blind, maker-run trial of green-passing lenses missed its primary endpoint (Posternack 2023). Net reading: relief remains unproven, since support is uncontrolled and the blinded test used lenses.

Magnitude: Headache improved in 55% of 3,232 treated attacks; no control group (Lipton 2023).

Shorter Attack Duration

Duration of the headache phase improved during the green phase of the Arizona trial (Martin 2021), and modestly during the white phase (Martin 2021). In the Pakistani trial, attack duration fell in all three arms, sham included (Mahmood 2025). Neither trial compared duration between arms.

Magnitude: Direction only: attacks shortened more with green than with white light in Arizona; the literature reports no outcome figure for duration (Martin 2021).

Less Light Sensitivity During Attacks

Photophobia (pain or discomfort caused by light) improved in about half of lamp-treated attacks in the open-label study (Lipton 2023). Green-enriched white light caused the least visual discomfort of four spectra during attacks (Sharp 2026), a different light form.

Magnitude: Photophobia improved in 53% of 3,232 treated attacks; no control group (Lipton 2023).

Better Sleep ⭕️ Not Central to Treat Migraine

Ability to fall and stay asleep improved during both light phases of the Arizona trial (Martin 2021), and sleep improved after about half of lamp-treated attacks (Lipton 2023). This bears on sleep quality, not on migraine itself. Both used single unvalidated questions.

Magnitude: Same-night sleep improved after 49% of 3,232 treated attacks; no control group (Lipton 2023).

Anxiety during attacks improved in about a third of lamp-treated attacks in the open-label buyer study (Lipton 2023). The authors note it may follow headache relief rather than act independently.

Magnitude: Anxiety improved in 34% of 3,232 treated attacks; no control group (Lipton 2023).

Less Acute Medication Use

Paracetamol use for attacks fell in all three arms of the Pakistani trial, including sham tDCS (Mahmood 2025). The Arizona trial could not assess medication change (Martin 2021).

Magnitude: Direction only: use fell in every arm, sham included; the literature reports no green-light-specific outcome figure (Mahmood 2025).

Speculative 🟨

Activation of the Body’s Own Opioid Pain Control

In rats, daily green light raised pain thresholds through spinal opioid signaling (Ibrahim 2017), reversed by naloxone (Ibrahim 2017). The basis is animal data only.

Weaker Retinal and Cortical Responses to Light

In migraine, green light evoked smaller eye responses than white, blue and red (Noseda 2016), and smaller brain responses than blue, amber and red (Noseda 2016). The basis is mechanistic; these are unvalidated markers.

Benefit-Modifying Factors

  • Genetic color-vision variants: Variants in OPN1LW/OPN1MW (genes for the red- and green-sensing cone pigments) cause red-green color deficiency. A man with protanomaly (weak red-cone function) reported less pain intensity but unchanged headache frequency (Cheng 2022).
  • Baseline headache frequency: In the Arizona trial, 6 of 7 episodic (fewer than 15 headache days a month) (Martin 2021) and 12 of 19 chronic migraine patients (15 or more) (Martin 2021) had at least 50% fewer headache days. No blood biomarker predicts response.
  • Sex: Participants were mostly women (all but two in Arizona, Martin 2021); no trial analyzed response by sex.
  • Pre-existing conditions: Co-existing fibromyalgia may add benefit, since the same protocol reduced fibromyalgia pain (Martin 2021); the Pakistani trial excluded people with photophobia, leaving the most light-sensitive group untested (Mahmood 2025).
  • Age: Lamp responders were 5 years younger than non-responders (Lipton 2023). Arizona participants averaged 52 years (range 24–72) (Martin 2021); Pakistani arm means were 24–30 years (Mahmood 2025). No response data exist for adults over 70.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: harms come from one group’s laboratory color-exposure sessions and from a single registry adverse-event posting (no events in 55 participants under green or white light, NCT03677206).

Medium 🟥 🟥

Headache Worsening During Light Exposure

In the Burstein group’s laboratory sessions, green light intensified attack headache in some patients, though in fewer than other colors (Noseda 2016), and the proportion rose with brightness (Nir 2018). Burstein later held stock options in a green-lamp company. A separate group found green-enriched white light did not raise attack pain (Sharp 2026), a different light form.

Magnitude: At 100 cd/m² (candela per square meter, a brightness unit), green light intensified attack headache in about 40% of patients (Nir 2018) versus about 80% for white, blue, amber and red light (Nir 2018); between attacks it triggered headache in 3% (Nir 2018) versus 16–19% (Nir 2018).

Low 🟥

Reduced Effect of Delayed Acute Medication

The acute protocol asks users to sit two hours in green light before taking usual attack medication (Lipton 2023). In a sumatriptan trial run by its manufacturer, early dosing outperformed late dosing (Scholpp 2004). Indirect: no green light study measured this.

Magnitude: Pain-free at two hours: 71.1% with early (Scholpp 2004) versus 54.3% with late sumatriptan (Scholpp 2004).

Evening Melatonin Suppression

In healthy adults, 555 nm green light suppressed melatonin (the night-time sleep hormone) as strongly as blue light at exposure onset (Gooley 2010). Indirect: laboratory exposure in healthy volunteers, not therapy lamps in migraine; migraine trials reported better, not worse, sleep (Martin 2021, Lipton 2023).

Magnitude: Direction only: suppression was strongest early in exposure and faded with duration; the literature reports no outcome figure for dim therapy lamps (Gooley 2010).

Visual Discomfort From the Light

During attacks, green-enriched white light still caused moderate visual discomfort, though less than other spectra (Sharp 2026). Indirect: white light enriched with green, not narrow-band green.

Magnitude: Discomfort 4.78 of 10 with green-enriched (Sharp 2026) versus 7.58 with blue-enriched white light (Sharp 2026).

Speculative 🟨

Seizure Provocation by Flickering Sources

Inexpensive LED strips can flicker, and flicker provokes seizures in photosensitive epilepsy (epilepsy in which flashing light triggers seizures). No green light migraine study reported seizures; the basis is mechanistic.

Retinal Light Injury at High Intensity

Visible light near the blue-green range can injure the retina at high light power; therapy lamps run far below such levels. The basis is mechanistic; no human reports exist.

Risk-Modifying Factors

  • Genetic factors: No gene variant affecting drug handling applies. Inherited red-green color deficiency (OPN1LW/OPN1MW variants) changes how green is perceived, but no harm data exist for this group.
  • Baseline light sensitivity: Between attacks, green light triggered headache in 3% of migraine patients tested (Nir 2018); no study has analyzed whether people with light sensitivity between attacks carry higher risk. No laboratory biomarker modifies risk.
  • Sex: No sex-specific harm data exist; study populations were overwhelmingly female.
  • Pre-existing conditions: Photosensitive epilepsy (seizures triggered by flickering light), retinal disease, and recent porfimer photodynamic therapy (a light-activated cancer treatment) (Photofrin label) raise concern; insomnia may raise the stakes of evening sessions, inferred from melatonin suppression by green light in healthy adults (Gooley 2010).
  • Age: Older adults sitting one to two hours in a dark room face a fall risk when standing; this is inferred, with no trial data. The Arizona trial enrolled adults up to 72 without reported harm (Martin 2021).

Key Interactions & Contraindications

Documented interactions:

  • Porfimer (Photofrin), a photodynamic therapy drug: Skin and eye photosensitivity to bright indoor light for at least 30 days; Avoid: bright or close-range lamps. The label also advises against staying in a darkened room during this period, which conflicts with dark-room sessions (Photofrin label).
  • Current migraine medications (paracetamol; other acute and preventive drugs not named in the reports): No interaction found; Arizona patients continued existing therapies with no side effects reported (Martin 2021); most Pakistani participants used paracetamol alongside green light (Mahmood 2025).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Triptans (migraine-specific serotonin-receptor drugs) and over-the-counter pain relievers (sumatriptan, rizatriptan, ibuprofen, naproxen, acetaminophen): Inferred from reduced efficacy of late dosing; waiting out a two-hour lamp session may lower the chance of attack relief. Mitigation: medication taken at the usual point in the attack.
  • Drugs that impair color vision or retinal function (ethambutol, hydroxychloroquine): Inferred from cone-pathway mechanism; impaired green-cone signaling may blunt benefit. Mitigation: response tracked with a headache diary.
  • Sunlight-photosensitizing drugs (doxycycline, hydrochlorothiazide, amiodarone): Inferred from photosensitization; their reactions are driven mainly by ultraviolet light, which green LEDs do not emit, so no consequence is expected.
  • St John’s wort (hypericin, a light-activated pigment): Inferred from photosensitization at visible wavelengths; possible skin or eye irritation at close range. Mitigation: lamp kept distant and dim.
  • Melatonin supplements: Inferred from melatonin suppression by green light; evening sessions may partly offset a melatonin dose. Mitigation: sessions held earlier in the day.
  • Migraine-preventive supplements (magnesium, riboflavin, coenzyme Q10): Inferred additive preventive effect via independent mechanisms; any added benefit is untested.
  • Other light treatments (bright white light boxes): Inferred opposing effect; bright broad-spectrum light can aggravate attack headache. Mitigation: sessions separated in time.
  • Transcranial direct current stimulation: Inferred additive effect on pain processing; combined use is under trial (NCT06943625) but unreported.

Populations who should avoid Green Light Therapy:

  • People whose attack headache intensifies under green light, documented in about 40% of patients at 100 cd/m² during attacks (Nir 2018).
  • People within 30 days of porfimer (Photofrin) dosing, for any bright or close-range lamp (Photofrin label).
  • People with photosensitive epilepsy using lamps that flicker (inferred from flicker-triggered seizures; no human data with therapy lamps).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Low brightness: Sessions at 4–100 lux, as in the Arizona trial (Martin 2021), limit headache worsening, which rises with intensity (Nir 2018).
  • Session ended if pain rises: Returning to darkness when headache intensity rises during exposure prevents prolonged light-induced worsening; no source gives a numeric threshold.
  • Rescue medication not delayed: Usual attack medication taken at its normal point, rather than after a two-hour session, avoids the reduced effect of late triptan dosing (Scholpp 2004).
  • Sessions before evening: Ending preventive sessions two to three hours before bedtime (common practice) avoids light near the evening melatonin rise, when green light suppresses melatonin and shifts the body clock (Gooley 2010).
  • Flicker-free sources: Lamps with constant-current drivers (steady power supplies) rather than low-cost dimmed strips reduce flicker-related seizure and visual-discomfort risk.
  • Safe dark-room setup: Clear walking paths and a dim night-light route prevent falls after one to two hours in near-darkness, particularly in older adults.

Therapeutic Protocol

Timing, session length, step-up of session time and cycling below follow common practice unless cited.

  • Preventive protocol (Arizona, Mohab Ibrahim): 525 nm green LED strip at 4–100 lux, 1–2 meters away, 1–2 hours daily in an otherwise dark room for 10 weeks, awake, light in the field of view (Martin 2021).
  • Acute protocol (Harvard, Rami Burstein; Allay Lamp): 520 ± 10 nm lamp at 5–10 cd/m², 4–6 feet behind or above, two hours during an attack with all other light off (Lipton 2023).
  • Short-course protocol (Pakistan): 525 ± 10 nm lamp, one hour daily, five days a week for four weeks, daytime, alongside usual medication (Mahmood 2025).
  • Competing approaches: Daily prevention (Arizona) and on-demand attack use (Harvard) are separate strategies; green light is used alone or added to drug prevention, with no head-to-head comparison against preventive drugs.
  • Time of day: The Pakistani trial used daytime sessions (Mahmood 2025); the Arizona trial asked for sessions at the same time every day, without fixing a clock time (Martin 2021). Daytime or early evening avoids bedtime melatonin effects.
  • Session structure: One continuous session; splitting has not been studied. Not a compound, so half-life does not apply, though pain relief in rats lasted four days after exposure ended (Ibrahim 2017).
  • Genetic factors: Red-green color deficiency may reduce frequency benefit while sparing pain relief (Cheng 2022); no other genetic factor guides use.
  • Sex: No sex-specific protocol exists; trial participants were mostly women.
  • Age: The Arizona protocol was used up to age 72 (Martin 2021); older adults may need brighter settings to read comfortably, staying within the trial range.
  • Baseline biomarkers: No blood test guides use; baseline monthly headache days and light sensitivity set the starting point for judging response.
  • Pre-existing conditions: Chronic migraine responded less often than episodic migraine (Martin 2021); fibromyalgia shares the same protocol (Martin 2021).

Discontinuation & Cycling

  • Duration: Trials ran 4 weeks (Mahmood 2025) to 10 weeks (Martin 2021); whether use is lifelong or a time-limited course is unstudied. Continued use is commonly judged by headache-diary response.
  • Withdrawal effects: None reported; no trial followed participants after stopping.
  • Tapering: Not needed; sessions can stop at once, as no dependence mechanism exists.
  • Persistence after stopping: In rats, pain relief lasted four days after the last exposure without tolerance (Ibrahim 2017); human persistence is unknown.
  • Cycling: No data support cycling; tolerance did not develop in rats (Ibrahim 2017).

Sourcing and Quality

  • Wavelength: Studied sources peak at 525 nm (Martin 2021) or at 520 nm within a 20 nm band (NCT04841083). Decorative “green” bulbs or screens may include blue or yellow light.
  • Brightness control: A dimmer allows staying within the studied range, 1–10 lux for the Allay Lamp (NCT04841083) to 4–100 lux in the Arizona trial (Martin 2021); inexpensive lux meters or phone apps allow checking.
  • Flicker: Constant-current, flicker-free drivers matter more than brand; pulse-width dimming (rapid on-off switching) in low-cost strips can flicker.
  • Products: The Allay Lamp, based on the Harvard group’s work, whose senior author held company stock options (Lipton 2023), and generic 525 nm LED strips; the Arizona trial used ledsupply.com strips (Martin 2021).
  • Testing: No independent third-party testing of green therapy lamps exists; spectrum claims are manufacturer statements.
  • Tinted glasses: Green-transmitting glasses are a different form, with null or feasibility-only trials (Posternack 2023, Nelli 2023).

Practical Considerations

  • Time to effect: Pain differences appeared by two weeks in the Pakistani trial (Mahmood 2025); the Arizona trial assessed headache days over 10 weeks (Martin 2021). Acute use was judged within two hours (Lipton 2023).
  • Common pitfalls: Lamps too bright, other light sources left on, falling asleep, irregular sessions, and no baseline headache diary against which to judge change.
  • Regulatory status: The Allay Lamp registry record describes it as a consumer product, not a medical device, not requiring 510(k) clearance (the US Food and Drug Administration’s premarket notification) (NCT04841083).
  • Cost and access: Inexpensive and freely available; no prescription is needed.
  • Funding asymmetry: Migraine drug trials are funded mainly by manufacturers, while a low-cost device has no comparable sponsor; insurers would gain from low-cost options, yet neither side has funded a large sham-controlled trial.
  • Time cost: One to two hours daily in a dark room is the main burden.

Interaction with Foundational Habits

  • Sleep: Potentiating in reports: sleep improved during treatment (Martin 2021), though evening green light can suppress melatonin (Gooley 2010). Ending sessions well before bedtime limits this effect; regular sleep timing also reduces migraine triggers.
  • Nutrition: No direct interaction. Regular meals and hydration remain standard migraine trigger control; 13–22% of participants per arm in the Pakistani trial reported skipping meals (Mahmood 2025).
  • Exercise: No direct interaction. The Pakistani protocol allowed exercising during sessions in the field of the lamp (Mahmood 2025); sessions can follow exercise but not replace daytime outdoor activity.
  • Stress management: Indirect, potentiating: stress as a reported trigger fell most in the green light arm (Mahmood 2025), and green light accompanied calmer attacks in buyers (Lipton 2023). Quiet dark-room sessions pair naturally with breathing or meditation practice.

Monitoring Protocol & Defining Success

Before starting, a baseline period of at least four weeks of headache diary records monthly headache days, attack pain on a 0–10 scale, acute medication days and a HIT-6 score, matching the measures used in the trials. Light sensitivity between attacks is also noted, although no study has tested whether it predicts light-induced worsening. No blood test is needed, because green light is not known to change any laboratory value.

Ongoing monitoring follows a fixed cadence: the diary continues daily, pain is rated at the start and end of each session, and summary measures are compared with baseline at 4 weeks, at 10–12 weeks, then every 3 months while use continues. A session that raises pain is a safety signal. A response is commonly judged at 10–12 weeks, the trial duration, and an absent response by then counts against continued use.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Monthly headache days No established target; track change from own baseline Expected to change At least 50% fewer days defined a responder in Martin 2021, where a headache day was a day with moderate to severe headache lasting 4 hours or more
Attack pain (0–10 numeric pain scale) No established target; track change from own baseline Expected to change; a rise during a session is a safety check Ratings at session start and end show whether exposure raises pain, the light-induced worsening described under Risks
Headache Impact Test-6 (HIT-6) score No established target; track change from own baseline Expected to change Covers the past 4 weeks; scores of 36–49 indicate little or no impact per NCT03677206
Acute medication days per month No established target; track change from own baseline Expected to change Dose timing relative to the session shows whether attack treatment was delayed

Qualitative markers:

  • Light sensitivity during and between attacks
  • Sleep onset and continuity on session days
  • Anxiety and calm during attacks
  • Ability to work and perform daily activities
  • Adherence: sessions completed per week

Emerging Research

  • Green light plus brain stimulation (NCT06943625): Randomized trial in Pakistan, about 40 participants, primary outcomes headache diary and pain at 4 weeks. Registered completion April 2026 has passed; still listed as recruiting, no results posted. A positive result would support an add-on role; a null result would weaken the 2025 trial’s signal (Mahmood 2025).
  • Arizona crossover registry (NCT03677206): Active, not recruiting; completion expected December 2026; results posted November 2025 (cited under disability). Positive final results would reinforce the one light-controlled dataset; null ones would remove the strongest support.
  • Green-enriched white light (NCT07898722): Randomized crossover, 40 participants, completed October 2025, no results posted. A positive result would offer an everyday lighting alternative; a null result would confine any benefit to narrow-band lamps.
  • Workplace lighting and migraine days (NCT07476053): Single-group study of about 20 adults, recruiting, monthly migraine days as primary outcome. A positive result would support ambient lighting changes; a null result would argue against small spectral adjustments.
  • Sham-light randomized trials: A 2026 review identifies blinded, pre-registered, sham-controlled trials as the missing evidence (Bain 2026); such a trial could confirm or erase the current benefit signal.
  • Weakening evidence from filters: A double-blind lens trial missed its primary endpoint (Posternack 2023), suggesting that wavelength effects may be smaller than open-label studies imply.
  • Photoreceptor pathway: Mouse work implicating cones (Tang 2022) conflicts with a human case implicating melanopsin cells (Cheng 2022); resolving this would shape lamp design.

Conclusion

Green light therapy is a drug-free approach in which people with migraine sit for one to two hours in dim, narrow-band green light, either daily to prevent attacks or during an attack. Its appeal for health-focused adults willing to commit time is clear: it is inexpensive, easy to obtain, and has produced no serious harms in the studies.

The human evidence points toward fewer headache days, less painful attacks and less headache-related disability, with softer signals for light sensitivity, sleep and anxiety during attacks. That evidence is thin. It rests on one small trial that always gave white light before green light, one small trial that assigned treatments by chance and whose comparison was an inactive brain-stimulation procedure rather than an inactive light, and open studies of people who had already bought a lamp. Almost no study has hidden the color of the light from participants, so expectation may explain part of the effect, and the one trial that did, of green-passing lenses, found no clear benefit.

The main risks are modest: light of any color, green included, can intensify headache during some attacks, waiting out a session can delay effective attack medication, and evening sessions may disturb sleep timing.

Much of the supportive work comes from researchers holding a pending patent on the method or a financial stake in a lamp company, and that lens trial was run by the lens maker. Green light remains a promising but unproven option, and how much it truly helps is unknown.

Top - Benefits - Risks - Protocol